Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection
There are no licensed vaccines against Plasmodium vivax. We conducted two Phase I/IIa clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vecto...
Main Authors: | Hou, M, Barrett, JR, Themistocleous, Y, Rawlinson, TA, Diouf, A, Martinez, FJ, Nielsen, CM, Lias, AM, King, LDW, Edwards, NJ, Greenwood, NM, Kingham, L, Poulton, I, Khozoee, B, Goh, C, Hodgson, SH, Mac lochlainn, D, Salkeld, J, Guillotte-Blisnick, M, Huon, C, Mohring, F, Reimer, JM, Chauhan, VS, Biswas, S, Lawrie, AM, Silk, SE, Minassian, AM, Draper, SJ, Mukherjee, P, Taylor, IJ, Cho, J, Nugent, FL, Long, CA, Moon, RW, Miura, K, Chitnis, CE |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Association for the Advancement of Science
2023
|
Similar Items
-
Immunogenicity of a Plasmodium vivax vaccine based on the duffy binding protein formulated using adjuvants compatible for use in humans
by: Francisco J. Martinez, et al.
Published: (2023-08-01) -
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial
by: Martinez, FJ, et al.
Published: (2024) -
Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: safety and parasite growth dynamics
by: Salkeld, J, et al.
Published: (2022) -
Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies
by: Payne, R, et al.
Published: (2017) -
Antibody responses to Plasmodium vivax Duffy binding and Erythrocyte binding proteins predict risk of infection and are associated with protection from clinical Malaria.
by: Wen-Qiang He, et al.
Published: (2019-02-01)